The additional (post hoc) analysis of results from Silence’s Phase II trial of Atu027 in pancreatic cancer is encouraging. We look forward to more comprehensive efficacy data from a larger Phase II prospective trial, which is due to commence over the next 18 months following completion of preclinical dose optimisation work.
